Jeff Kmetz

Jeff Kmetz, our Chief Business Officer, has over 25 years of global pharmaceutical and biotechnology industry experience. Throughout his career, Mr. Kmetz has held senior roles with increasing levels of responsibility in marketing, commercial and business development. Most recently, he served as Chief Business Officer at Pulse Biosciences, managing the Oncology development for the company’s Nano-Pulse Stimulation technology. Prior to that, he was Head of Commercial and Business Development along with Strategic Marketing at Pharmacyclics, where he was instrumental in formulating and executing the commercialization and life cycle management of best-in-class BTK inhibitor ibrutinib — the asset which prompted the company’s acquisition by AbbVie for $21 billion in 2015. Prior to that, Mr. Kmetz served as Director of U.S. Hematology Marketing at Alexion and led multiple initiatives in sales and marketing. Before Alexion, Mr. Kmetz was Hematology Business Unit Lead at Bayer, managing its hematology portfolio and brands. Mr. Kmetz holds a B.S. from Virginia Tech.

Jeff Kmetz is the Chief Business Officer at Ascentage Pharma, based in United States, North America. With a background in Biotechnology, Jeff Kmetz has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.